Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients  by Sanz, J.C. et al.
[5–12]. Therefore, our results do not support antibiotic pro-
phylaxis for urinary catheter removal in non-genitourinary
surgical patients.
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Abstract
From July 2007 to June 2009, all pneumococci causing invasive
pneumococcal disease in our hospital were serotyped. Antimi-
crobial susceptibility was determined by microdilution. Molecular
typing was performed by pulsed-ﬁeld gel electrophoresis and by
multilocus sequence typing. Among 251 invasive pneumococci,
serotype 8 was the most frequent (13.5%). All serotype 8 strains
were susceptible to penicillin; however, 61.8% (21/34) were
co-resistant to erythromycin, levoﬂoxacin and tetracycline and
identical to the Sweden15A-ST63 clone. Serotype 8 was signiﬁ-
cantly more frequent among human immunodeﬁciency virus
(HIV)-infected patients (36.5%). The high prevalence of this non-
conjugate vaccine multiresistant serotype 8 is a cause for con-
cern mainly in HIV-infected patients.
Keywords: HIV-infected patients, multidrug-resistant pneumo-
cocci, Streptococcus pneumoniae serotypes, vaccines
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The pneumococcal conjugate 7-valent vaccine (PCV7) was
approved in Spain for children in June 2001 and was included
in the paediatric vaccination calendar of the area of Madrid
in November 2006. The introduction of this vaccine changed
the distribution of Streptococcus pneumoniae serotypes and its
antimicrobial susceptibility patterns [1]. Recently, the 13-
valent pneumococcal conjugate vaccine (PCV13) has been
granted marketing authorization in Europe. At present, most
of the circulating serotypes in Spain are covered by this vac-
cine [1]. Serotype 8 is included in the 23-valent pneumococ-
cal polysaccharide vaccine (PPV23) but is not incorporated in
any of the conjugate vaccines. This serotype has been
reported as a common cause of invasive pneumococcal dis-
ease (IPD) in our country [1] and became the most frequent
in our hospital during 2007–2009. The aim of this study was
to analyse the prevalence and the antimicrobial susceptibility
of the main S. pneumoniae serotypes causing IPD in our cen-
tre over this 2-year period.
From July 2007 to June 2009, all pneumococci isolated
from normally sterile clinical samples at the Hospital General
Universitario Gregorio Maran˜o´n of Madrid (a 1550-bed ter-
tiary general hospital attending a population of 715 000
inhabitants) were serotyped by latex agglutination (Pneumot-
est-Latex kit, Statens Serum Institut, Copenhagen, Denmark)
and Quellung reaction with factor antisera (Statens Serum
Institut, Copenhagen, Denmark). Minimum inhibitory concen-
trations (MICs) of penicillin, cefotaxime, erythromycin, levo-
ﬂoxacin, tetracycline and trimethoprim/sulfamethoxazole
were determined using a commercialized panel (MSTRP+1,
MicroScan; Siemens, West Sacramento, CA, USA). Penicillin
susceptibility breakpoints were based on CLSI 2007 and
2008 criteria [2,3]. Serotype 8 isolates were typed by
pulsed-ﬁeld gel electrophoresis (PFGE) [4]. Representative
strains (at least one per PFGE group) were studied by mul-
tilocus sequence-typing (MLST) [5]. The quinolone-resis-
tance-determining-regions (QRDR) of the gyrA and parC
genes were ampliﬁed and sequenced using a previously
described method [6].
A total of 251 isolates from 243 patients with community-
acquired IPD (age <1–98 years; 155 male patients; 36 chil-
dren <5 years) were studied. Fifty-two patients (32–68 years;
40 male) were infected by the human immunodeﬁciency virus
(HIV+). Recurrent disease was deﬁned as two or more IPD
episodes in the same patient separated at least by 30 days.
Four patients (1.6%) had two recurrent infections (three of
them were HIV+), and two (0.8%) had three recurrences
(one of them was HIV+). Ten serotypes hampered 74.5% of
the isolates: serotype 8 (13.5%), 19A (13.1%), 7F (11.2%), 1
(8.0%), 5 (8.0%), 3 (7.2%), 14 (4.0%), 12F (4.0%), 19F (2.8%)
and 9V (2.8%). Table 1 shows the antimicrobial susceptibility
of the most frequent serotypes. All serotype 8 strains
(n = 34) were susceptible to penicillin and cefotaxime. How-
ever, the multiresistance patterns erythromycin-levoﬂoxacin-
tetracycline (61.8%), erythromycin-levoﬂoxacin-trimethoprim/
sulfamethoxazole (47.1%), erythromycin-tetracycline-trimetho-
prim/sulfamethoxazole (52.9%) and levoﬂoxacin-tetracycline-
trimethoprim/sulfamethoxazole (47.1%) were signiﬁcantly
more frequent in serotype 8 isolates in comparison with the
remaining 217 isolates (0.0%, 0.0%, 11.1% and 0.0%, respec-
tively; p <0.001). All strains (n = 21; 8.4%) co-resistant to
erythromycin and levoﬂoxacin belonged to serotype 8.
Within serotype 19A (n = 33) the rates of multi-resistance
to penicillin-erythromycin-tetracycline (66.7%), penicillin-
erythromycin-trimethoprim/sulfamethoxazole (42.4%), penicil-
lin-tetracycline-trimethoprim/sulfamethoxazole (42.4%) and
erythromycin-tetracycline-trimethoprim/sulfamethoxazole (39.4%)
were signiﬁcantly higher (p <0.001) in comparison with
the remaining 218 isolates (8.3%, 5.0%, 4.6% and 13.3%,
respectively). All 19A strains were susceptible to
levoﬂoxacin.
Thirty-one of the 34 serotype 8 strains (20 levoﬂoxacin-
erythromycin-resistant, and 11 susceptible to both antimicro-
bials) were available for molecular typing. Among them, a
total of six different PFGE patterns were observed. The 20
levoﬂoxacin- and erythromycin-resistant isolates had a com-
mon PFGE pattern, different to the susceptible strains and
identical to that of the Pneumococcal Molecular Epidemiol-
ogy Network (PMEN) clone Sweden15A-ST63 (ATCC BAA-
661) [4]. This identity was conﬁrmed after MLST analysis
(ST63). Among a subset of 16 serotype 8 levoﬂoxacin-resis-
tant strains, the S79F parC mutation was detected in all of
them and S81F, S81Y and E85K gyrA mutations in 12, 2 and
2 isolates, respectively.
In HIV+ patients, serotype 8 (36.5%) and serotype 8 with
co-resistance to erythromycin and levoﬂoxacin (25.0%) were
signiﬁcantly more frequent (p <0.001) than in other patients
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(7.5% and 4.0%, respectively). Table 2 shows the distribution
of serotype 8 in HIV+ and in other patients.
In this series serotype 8 was the most frequent and it was
mainly detected in adult HIV+ patients. Even though serotype
8 seems to be more widespread in adults [7], it has not been
found as a common cause of IPD in the HIV+ population [8].
All serotype 8 strains were susceptible to penicillin; how-
ever, co-resistance to erythromycin and levoﬂoxacin was
common. The antibiotic-resistant serotype 8 isolates were
identical to the Sweden 15A-ST63 PMEN clone. This clone
was initially identiﬁed as serotype 15A [9]. ST63 strains
could express different capsular types [10], suggesting fre-
quent capsular switching events [9]. The terminology to des-
ignate this levoﬂoxacin-resistant serotype 8 clone would be
therefore Sweden 15A-8-ST63.
Over the last few years serotype 19A has emerged as the
main multiresistant non-PCV7 serotype [11], contributing to
the increase in erythromycin resistance observed in our
country [12,13]. However, serotype 8 has not been usually
reported among erythromycin-resistant strains [14]. Fluoro-
quinolone-resistant serotype 8 has emerged recently in Spain
[15]. Resistance of pneumococci to levoﬂoxacin in Spain rose
from 0.1% in 2002 to 1.3% in 2007 [1]. This increase in the
resistance in adults has been correlated with the consump-
tion of ﬂuoroquinolones for the treatment of respiratory
infections [13]. However, no speciﬁc prophylaxis with quinol-
ones was systematically administered to HIV+ patients in our
centre. The PPV23 is recommended for HIV+ adult patients
[16] and recently the use of the pneumococcal conjugate
vaccines has been proposed in this population [17].
None of the patients included in this study received any
conjugate vaccine. Introduction of the paediatric conjugate
vaccine has been associated with an overall decrease in inva-
sive pneumococcal disease among HIV+ adults, despite
increased disease caused by non-vaccine serotypes [18]. These
changes may lead to a replacement of levoﬂoxacin-resistant
vaccine strains by levoﬂoxacin-resistant non-vaccine isolates
[19]. The high prevalence of serotype 8 resistant to erythro-
mycin and levoﬂoxacin may limit in our area the empirical use
of these antibiotics in HIV+ patients. As clonal spread of other
levoﬂoxacin-resistant serotypes has been previously described
[20], the emergence of this serotype 8 clone is an additional
cause of clinical and epidemiological concern.
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Abstract
Patient-related risk factors for invasive Staphylococcus aureus
infection overlap with those for periprosthetic joint infections
(PJIs). We compared these factors and clinical characteristics
between 17 exogenous and 40 haematogenous PJIs caused by
S. aureus. Exogenous cases presented signiﬁcantly more often
with damaged periprosthetic soft tissue, whereas haematogenous
cases more often had systemic signs of infection, such as fever,
chills, and sepsis syndrome. However, comorbid conditions asso-
ciated with S. aureus infection and/or PJIs did not differ between
the two groups. These ﬁndings imply that patient-related risk
factors for S. aureus infection do not help to predict the mode
of infection acquisition in prosthetic joints.
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Staphylococcus aureus is one of the most common pathogens
of periprosthetic joint infections (PJIs). The mode of infection
is either exogenous (mainly perioperatively acquired) or hae-
matogenous from a distant source [1]. Interestingly, patient-
related risk factors for invasive S. aureus infection partially
overlap with those for PJIs [2,3]. Patients with multiple risk
factors are prone to develop postoperative complications
[4]. However, these factors and clinical characteristics for
exogenous and haematogenous PJIs caused by S. aureus have
not been compared. Therefore, we retrospectively evaluated
demographic variables, comorbidities, clinical and laboratory
values at admission and 30-day mortality rates between
exogenous and haematogenous infections within our cohort
of hip and knee PJIs.
Patient charts of PJI cases caused by S. aureus were
reviewed in detail. Diagnosis included S. aureus in ‡2 speci-
mens (tissue biopsy or synovial ﬂuid) or, in cases of S. aureus
sepsis-related death, acute inﬂammation in histopathology
specimens at necropsy. Exogenous PJI included diagnosis
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